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MDAN-21, 7′-{2-[(7-{2-[({(5α,6α)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphin-6-yl}-aminocarbonyl)metoxy]-acetylamino}
-heptylaminocarbonyl)-methoxy]-acetylamino}-naltrindole, a bivalent opioid ligand containing a mu-opioid receptor agonist
(derived from oxymorphone) linked to the delta-opioid receptor antagonist (related to naltrindole) by a spacer of 21 atoms, was
reported to have potent analgesic properties in mice. Tolerance, physical dependence, and conditioned place preference were not
evident in that species. The finding that bivalent ligands in this series, with spacers 19 atoms or greater, were devoid of tolerance
and dependence led to the proposal that MDAN-21 targets heteromeric mu-delta-opioid receptors. The present study focused on
its eﬀects in nonhuman primates (Macaca mulatta), a species with a physiology and behavioral repertoire not unlike humans.
With regard to opioids, this species usually better predicts clinical outcomes. MDAN-21 substituted for morphine in morphine-
dependent monkeys in the remarkably low dose range 0.006–0.032mg/kg, subcutaneously. Although MDAN-21 failed to produce
reliable thermal analgesia in the dose range 0.0032–0.032mg/kg, intramuscularly, it was active in the same dose range and by the
same route of administration, in the capsaicin-induced thermal allodynia assay. The results suggest that MDAN-21 may be useful
in the treatment of opioid dependence and allodynia. The data provide additional evidence that opioid withdrawal is associated
with sensitized pain.
1. Introduction
The alkaloid morphine has been used in the treatment
of pain, cough, and diarrhea. Unfortunately, unpleasant
and/or potentially dangerous side eﬀects such as respiratory
depression, nausea, vomiting, and constipation can accom-
pany its use. Psychological and physiological processes such
as abuse, tolerance, and physical dependence have been
associated with chronic use and limit the utility of morphine
and other mu-opioid agonists in the treatment of chronic
pain.
In a continuing search for potent analgesics free of these
undesirable side eﬀects, many analogues of morphine and
numerous semisynthetic and synthetic derivatives have been
introduced. The evolution of this search was summarized in
a succinct review of the exciting but vain quest for the Holy
Grail of opioid research [1]. Results of an investigation of the
eﬀects of leucine and methionine enkephalin on morphine-
induced analgesia suggested an interaction between mu- and
delta-opioid receptors [2]. Over a decade later, investigators
found that naltrindole, a selective delta-opioid receptor
antagonist, blocked the morphine tolerance without
diminishing its antinociceptive potency [3]. These reports
and the finding that G-protein-coupled opioid receptors
existed as heterodimers: mu-kappa [4], mu-delta [5, 6],
and kappa-delta [7] led to a hypothesis-driven synthesis
[8] of a series of conjugates containing the mu-opioid
receptor agonist (derived from oxymorphone) linked with
delta-opioid receptor antagonist (related to naltrindole)
with spacers ranging from 16 to 21 atoms [9]. Studies in
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Figure 1: Chemical structure of MDAN-21.
mice indicated that 7′-{2-[(7-{2-[({(5α,6α)-4,5-Epoxy-
3,14-dihydroxy-17-methylmorphin-6-yl}-aminocarbonyl)-
metoxy]-acetylamino}-heptylaminocarbonyl)-methoxy]-acet-
ylamino}-naltrindole or MDAN-21, (see Figure 1), with a
25.4 A˚ spacer, (21-atoms), was the most potent analgesic
of the series. Significantly, naloxone, an opioid receptor
antagonist, failed to precipitate withdrawal signs after
chronic administration. It was subsequently shown that
MDAN-21-treated mice failed to develop conditioned place
preference [10]. These properties suggested that MDAN-21
may, to a significant extent, fulfill the long quest for a
strong opioid analgesic with greatly reduced side eﬀects.
We decided to determine MDAN-21’s eﬀects on morphine-
induced physical dependence and explore its analgesic
profile in nonhuman primates. The rhesus monkey study
models were selected because of their excellent relationship
to the behavioral expressions of opioid eﬀects in humans
and their predictive value regarding pharmacotherapy [11]
especially regarding opioids.
2. Material and Methods
2.1. Subjects. Male and female rhesus monkeys (Macaca
mulatta) served as subjects. All monkeys had prior exposure
to drugs and to the behavioral procedures in which they
were tested. The subjects in the substitution of morphine
assay were housed in groups, whereas those in the thermal
nociception and capsaicin-induced thermal allodynia assays
were individually housed. Food and water were freely
available. Their diet consisted of Purina Lab Diet Fiber-Plus
Monkey Biscuits no. 5049 (PMI Feeds, Inc., St. Louis, MO)
supplemented with fresh fruit twice weekly. A 12 h light/12 h
dark cycle was in eﬀect (lights on from 7AM–7PM).
Animal maintenance and research were conducted in
accordance with the guidelines provided by the NIH Com-
mittee on Laboratory Animal Resources. The facility was
licensed by the United States Department of Agriculture
and accredited by the Association for the Assessment and
Accreditation of Laboratory Animal Care. The protocols
were approved by the Institutional Animal Care and Use
Committee. The health of the monkeys was monitored daily
by technical and veterinary staﬀ. Monkeys had visual, audi-
tory and olfactory contact with other monkeys throughout
the study. Monkeys also had access to puzzle feeders, mirrors,
and chew toys to provide environmental enrichment. Nature
videotapes or music were played at least twice a week in all
housing rooms.
2.2. Substitution for Morphine Assay. Twenty-four monkeys
in the weight range 3.5–7.5 kg comprised the group tested.
The assay was based on that originally described by Deneau
[12]. Modifications follow. Morphine was given subcuta-
neously (s.c.) daily at 6 AM, 12 noon, and 6 PM. All the
animals had received morphine for at least 3 months and
were maximally dependent on morphine. At least 4 mon-
keys/treatment were used and a minimal two-week wash-out
period was allowed between testing. The assay was modified
as indicated below [13, 14]. It was initiated by the injection
(s.c.) of the test drug or control substances (morphine and
vehicle) into animals in a group that had not received mor-
phine for 14-15 hr and showed definite signs of withdrawal.
Each animal was randomly chosen to receive one of the
following treatments: (a) a dose MDAN-21; (b) morphine
sulfate control (4.0mg/kg); (c) vehicle control (1.0mL/kg).
Withdrawal signs were scored, absent, or present, once
during each of five consecutive 30-min observation periods.
Withdrawal signs included slowing of movement, drowsiness
(sitting with eyed closed and lethargic or being indiﬀerent
to surroundings), fighting, vocalizing, rigidity of abdom-
inal muscles, vocalization during palpation of abdominal
muscles, restlessness (pacing), tremors, coughing, retching,
vomiting, wet-dog shakes, and masturbation. The observer
was “blind” regarding the assignment of treatments. The
cumulative number of withdrawal signs was analyzed using
the Kruskal-Wallis Analysis of Variance (ANOVA) and post
hocMann-WhitneyU Tests. The Stat View statistical package
(Brainpower, Agoura Hills, CA) was utilized for these
analyses. In all cases, significance (P) was set at 0.05.
2.3. Assay of Thermal Nociception. Three adult rhesus mon-
keys were studied in this assay as described previously [15].
They were seated in acrylic restraint chairs so that their tails
hung down freely. During tail-withdrawalmeasurements, the
bottom 15 cm of each monkey’s shaved tail was immersed
in a thermal container of warm water. If the subject did
not withdraw its tail within 20 s, the tail was removed from
the water by the experimenter, and a latency of 20 s was
assigned to that measurement. Experiments were conducted
no more than once a week. A stopwatch was used to measure
and record time intervals. Each test session consisted of
multiple cycles. Before MDAN-21 administration, baseline
tail-withdrawal latencies from 38 and 50◦C water were
determined. Testing continued only if tail withdrawal from
38◦C water did not occur before the 20 s cutoﬀ, and if tail
withdrawal occurred in ≤2 s from 50◦C water. All monkeys
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met this criterion before every test session. The eﬀects of
MDAN-21 intramuscularly (i.m.) were evaluated using a
time-course procedure, in which a single dose of MDAN-
21 (0.0032–0.32mg/kg) was administered at the start of the
session, and tail withdrawal latencies from 50◦C water were
redetermined 3, 6, 10, 18, 32, 56, and 100min after the
injection.
MDAN-21 was completely ineﬀective up to the highest
doses tested in twomonkeys. Accordingly, a follow-up exper-
iment was conducted in these two monkeys to determine
whether MDAN-21 might function as an antagonist of
the high-eﬃcacy mu-agonist methadone. For these studies,
monkeys were pretreated with vehicle or 0.32mg/kg MDAN-
21 15min before treatment with 0.32mg/kg methadone.
Tail-withdrawal latencies were then determined 10, 20, and
30min after methadone administration. Drug eﬀects were
expressed as Percent Maximum Possible Eﬀect (%MPE)
using the following equation: “%MPE = (Test Latency −
Baseline Latency)/(20 − Baseline Latency)∗100”, where “Test
Latency” was the tail-withdrawal latency from 50◦C water
obtained during each cycle after drug administration, “Base-
line Latency” was the latency from 50◦C water during the
baseline determinations before drug injection, and “20” was
the cutoﬀ latency in s.
2.4. Assay of Capsaicin-Induced Thermal Allodynia. Three
diﬀerent male rhesus monkeys 5–12 kg were studied. Mon-
keys were seated in acrylic restraint chairs as described
above. To determine tail-withdrawal latencies, the lower
15 cm of each monkeys shaved tail was immersed into a
thermal container of warm water heated to the designated
temperature (see below for temperatures). The latency in
seconds for the monkey to remove its tail from the water
was measured using a hand-held stopwatch. If the subject
did not withdraw its tail within 20 s, the tail was removed
from the water by the experimenter, and a latency of 20 s was
assigned to that measurement. Experimental sessions were
conducted once per week. At the beginning of each session,
tail withdrawal latencies were determined for each monkey
from water heated to 38, 42, 46, and 50◦C, and the order of
temperature presentations was randomized across sessions.
By this procedure, baseline temperature-eﬀect curves were
determined in each monkey at the beginning of each
session, and the highest temperature to produce a tail
withdrawal latency >15 s was identified. Water heated to this
“threshold” temperature then served as the thermal stimulus
for subsequent studies of allodynia during that session. The
threshold stimulus intensity was 42◦C for two monkeys and
46◦C for the third monkey throughout the study.
Allodynia was elicited by topical application of capsaicin
as described previously [15, 16]. Following baseline tail
withdrawal latency determinations, a topical patch treated
with capsaicin solution or vehicle was prepared as described
below (see Drugs), and the patch was applied to a region
approximately 7 cm from the bottom of the tail for 5min.
After 5min, the patch was removed. Tail withdrawal latencies
were then redetermined 15, 30, 45, and 60min after patch
removal using the thermal stimulus identified from the
baseline temperature-eﬀect curve in each monkey (i.e., 42◦C
in two monkeys, 46◦C in the third monkey). MDAN-21
(0.0032–0.32mg/kg, i.m.) was administered 15min before
application of the capsaicin patch. Morphine (1.0mg/kg,
i.m., 15min pretreatment) was tested for comparison.
Raw tail withdrawal latencies obtained 15, 30, 45, and
60min after removal of the capsaicin patch were con-
verted to Percent Maximum Possible Eﬀect (%MPE) using
the equation %MPE = [(Test Latency − Capsaicin Alone
Latency)/(20 − Capsaicin Alone Latency)∗100)], where “test
latency” was the tail withdrawal latency obtained at each time
point after drug pretreatment + capsaicin patch treatment,
and “Capsaicin Alone Latency” was the latency obtained
at the corresponding time point after treatment with the
capsaicin patch alone.
2.5. Drugs. MDAN-21 was synthesized by Dr. Eyup Akgun
(Medicinal Chemistry Laboratory, Dr. Philip Portoghese,
Director). Morphine sulfate was purchased from Mallinck-
rodt, Inc., Hazelwood, MO. Methadone HCl was provided
by the NIDA Drug Supply Program. All drugs were dissolved
in sterile water for injection (Hospira, Inc., Forest Hills,
IL). Capsaicin (Sigma Chemical Co., St. Louis, MO) was
dissolved in vehicle composed of 70% alcohol and 30% sterile
water and was delivered transdermally (topical patch) as
described previously [15, 16]. The concentration of capsaicin
in the solution was individually determined for each monkey
as the lowest concentration to produce sustained decreases
in tail-withdrawal latencies from the threshold temperature
to ≤5 s throughout the 1 hr testing period (0.61mg/mL
(2mM)) for all three monkeys in the study. Within 30 s
of preparing the capsaicin patch, it was secured onto the
monkey’s tail with elastic tape and left on for 5min.
3. Results
3.1. Substitution for Morphine in Morphine-Dependent Rhesus
Monkeys Assay. Results of this assay are illustrated in
Figure 2. It is evident that MDAN-21 had a short onset and
long duration of action, that is, it eﬀectively suppressed with-
drawal as soon as 30min and was still eﬀective at 150min.
MDAN-21 and morphine suppressed the full spectrum of
withdrawal signs exhibited by the vehicle controls. The eﬀec-
tive dose range was 0.006–0.03mg/kg. The Kruskal-Wallis
ANOVA P values are as follows: 30min-0.01; 60min-0.0002;
90min-0.0002; 120min-0.0001; 150min-0.0001. Post hoc
Mann-Whitney comparisons with probability values of 0.05
or less are indicated in figure legends and with appropriate
superscript letters in Figure 2.
3.2. Assay of Thermal Nociception. The mean ± S.E.M
baseline tail withdrawal latency from 50◦C was 0.75 ±
0.18 s. Figure 3 shows the time course of antinociceptive
eﬀects produced by doses of 0.0032–0.32mg/kg MDAN-21
in three individual monkeys. In monkey M1470 (one of
the two males), MDAN-21 doses of 0.0032 and 0.032mg/kg
produced a dose-dependent increase in tail withdrawal
latencies that peaked after 18 and 32min and then dissipated
after 56min. However, in the other two monkeys, MDAN-
21 doses of 0.032 and 0.32mg/kg were largely ineﬀective,
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Figure 2: Eﬀects of MDAN-21, morphine, and vehicle in morphine-dependent monkeys in spontaneous withdrawal. aSignificantly less
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Figure 3: Eﬀects of MDAN-21 in individual monkeys tested in a warm-water tail-withdrawal assay of thermal nociception. Abscissae:
minutes after administration of MDAN-21 (log scale). Ordinates: percent maximum possible eﬀect (%MPE). The identification number of
the monkey is shown in the upper left of each panel.
producing only small increases in tail-withdrawal latencies
after 6min in monkey M1472. Higher doses were also tested
in M1472 (2.6mg/kg) and M1475 (1.0mg/kg) and these
doses were also ineﬀective (maximum eﬀect of 15% MPE at
any time in either monkey; data not shown).
Figure 4 shows the eﬀects of pretreatment with vehicle
or MDAN-21 on the antinociceptive eﬀects of 0.32mg/kg
methadone in monkeys M1472 and M1475. After vehi-
cle pretreatment, methadone produced a time-dependent
antinociception that peaked after 20–30min. Pretreatment
with 0.32mg/kg MDAN-21 had no eﬀect on methadone
antinociception in either monkey.
3.3. Capsaicin-Induced Thermal Allodynia Assay. The mean
± S.E.M baseline tail withdrawal latency at the threshold
temperature was 19.59± 0.41 s, and treatment with capsaicin
alone reduced tail withdrawal latencies at the threshold
temperature to mean ± S.E.M. values of 1.71 ± 0.42, 1.
66 ± 0.23, 1.65 ± 0.41, and 1.49 ± 0.10 s at times 15, 30,
45, and 60min after capsaicin patch removal, respectively.
Figure 5 shows that pretreatment with MDAN-21 (0.0032–
0.32mg/kg) produced a dose- and time-dependent preven-
tion of capsaicin-induced allodynia. The highest dose of
0.32mg/kg MDAN-21 produced peak antiallodynic eﬀects
after 15min, and these eﬀects dissipated after 45 to 60min.
For comparison, the antiallodynic eﬀect of 1.0mg/kg mor-
phine peaked after 30min and remained at levels greater than
50% MPE in all three monkeys at 45min and in two of three
monkeys at 60min.
4. Discussion
MDAN-21 was very eﬀective in suppressing withdrawal signs
in morphine-dependent monkeys. Its action was prompt.
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It had a remarkably long duration of action compared
to that in the capsaicin-thermal assay in nondependent
monkeys. Perhaps, MDAN-21 is much more eﬀective in
situations involving physical dependence. Increased pain
sensitivity in chronic pain patients and opioid abusers has
been reported [17–19].MDAN-21 failed to produce a reliable
antinociceptive eﬀect in the assay of thermal antinociception
in nondependent monkeys. In one monkey, a dose of 0.032,
MDAN-21 was fully eﬀective, but neither this dose nor a
10-fold higher dose of 0.32mg/kg was active in the other
two monkeys. Conversely, MDAN-21 was as eﬀective as
morphine in all monkeys tested in the assay of capsaicin-
induced thermal allodynia.
This profile of results is consistent with the possi-
bility that MDAN-21 does not readily cross the blood-
brain barrier in rhesus monkeys [15]. On the other hand,
suppression of withdrawal signs in morphine-dependent
monkeys by MDAN-21 suggests that it crosses the blood-
brain barrier. It is known that quaternary compounds, do
not readily cross the blood-brain barrier. Indeed, quaternary
morphine compounds were reported virtually inactive in
morphine-dependent rhesus monkeys and practically devoid
of antinociceptive activity in mice [20]. The variability in
eﬀects produced by MDAN-21 in the assay of thermal
nociception did not appear to result from low eﬃcacy of
MDAN-21 at mu-opioid receptors. If MDAN-21 had failed
to produce antinociception in 2 of 3 monkeys due to low
eﬃcacy, then it would be expected to antagonize the eﬀects of
a higher eﬃcacy mu-agonist in these twomonkeys. However,
MDAN-21 failed to antagonize the antinociceptive eﬀects of
methadone in either monkey. Nevertheless, it is possible that
higher doses might have achieved a robust antinociceptive
eﬀect. Finally, species diﬀerences in mu-delta interactions on
neural substrates that mediate thermal antinociception may
be involved [21–23].
Nevertheless, MDAN-21was potently active in the
capsaicin-induced thermal allodynia assay in the dose range
of 0.032–0.32mg/kg. It also attenuated withdrawal signs in
morphine-dependent monkeys in spontaneous withdrawal
for a longer time period. The results are in accord with
the findings of other investigators that pain sensitivity is
increased in opioid-treated animals, chronic pain patients
6 International Journal of Medicinal Chemistry
and opioid abusers (see references above). The results also
suggest that MDAN-21 may be useful in the pharmacother-
apy of chronic pain and chronic opioid use.
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